Show simple item record

dc.contributor.authorGarcía-Gutiérrez, Valentin
dc.contributor.authorBreccia, Massimo
dc.contributor.authorJabbour, Elias
dc.contributor.authorMauro, Michael
dc.contributor.authorCortes, Jorge E.
dc.date.accessioned2023-11-28T16:13:30Z
dc.date.available2023-11-28T16:13:30Z
dc.date.issued2022-12
dc.identifier.citationGarcía-Gutiérrez, V., Breccia, M., Jabbour, E., Mauro, M., & Cortes, J. E. (2022). A clinician perspective on the treatment of chronic myeloid leukemia in the chronic phase. Journal of Hematology and Oncology, 15(1), Article 90. https://doi.org/10.1186/s13045-022-01309-0en_US
dc.identifier.urihttp://hdl.handle.net/10675.2/624908
dc.description.abstractTyrosine kinase inhibitors (TKIs) have vastly improved long-term outcomes for patients with chronic myeloid leukemia (CML). After imatinib (a first-generation TKI), second- and third-generation TKIs were developed. With five TKIs (imatinib, dasatinib, bosutinib, nilotinib, and ponatinib) targeting BCR::ABL approved in most countries, and with the recent approval of asciminib in the USA, treatment decisions are complex and require assessment of patient-specific factors. Optimal treatment strategies for CML continue to evolve, with an increased focus on achieving deep molecular responses. Using clinically relevant case studies developed by the authors of this review, we discuss three major scenarios from the perspective of international experts. Firstly, this review explores patient-specific characteristics that affect decision-making between first- and second-generation TKIs upon initial diagnosis of CML, including patient comorbidities. Secondly, a thorough assessment of therapeutic options in the event of first-line treatment failure (as defined by National Comprehensive Cancer Network and European LeukemiaNet guidelines) is discussed along with real-world considerations for monitoring optimal responses to TKI therapy. Thirdly, this review illustrates the considerations and importance of achieving treatment-free remission as a treatment goal. Due to the timing of the writing, this review addresses global challenges commonly faced by hematologists treating patients with CML during the COVID-19 pandemic. Lastly, as new treatment approaches continue to be explored in CML, this review also discusses the advent of newer therapies such as asciminib. This article may be a useful reference for physicians treating patients with CML with second-generation TKIs and, as it is focused on the physicians’ international and personal experiences, may give insight into alternative approaches not previously considered.en_US
dc.language.isoenen_US
dc.relation.url10.1186/s13045-022-01309-0en_US
dc.subjectChronic myeloid leukemiaen_US
dc.subjectFirst-line treatmenten_US
dc.subjectTreatment switchingen_US
dc.subjectTreatment-free remissionen_US
dc.subjectTyrosine kinase inhibitorsen_US
dc.titleA clinician perspective on the treatment of chronic myeloid leukemia in the chronic phaseen_US
dc.typeAbstracten_US
dc.contributor.departmentAugusta Universityen_US
dc.identifier.journalJournal of Hematology and Oncologyen_US
refterms.dateFOA2023-11-28T16:13:32Z


Files in this item

Thumbnail
Name:
s13045-022-01309-0.pdf
Size:
892.8Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record